Clinical Trial Update: Safety and Initial Efficacy Study of the Vortx Rx for Treatment of Benign Prostatic Hyperplasia (Canada) [NA]

View source ↗

Summary

A Canadian clinical trial evaluating Vortx Rx for benign prostatic hyperplasia has been withdrawn, and safety/initial efficacy data will not be reported.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Benign Prostatic Hyperplasia

Drugs mentioned

• Vortx Rx

Snippet

Sponsor: HistoSonics, Inc. | Conditions: Benign Prostatic Hyperplasia (BPH) | NA | Status: WITHDRAWN